Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EvER-ILD 3
2023-510507-21-00Phase 3Authorised
- Sponsor
- CHRU Tours
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD) comparing Rituximab + mycophenolate mofetil with Placebo + mycophenolate mofetil (2 arms). Primary endpoint: Change in FVC (% predicted) from baseline to week 24. Planned start Oct 2024; status: authorised.
02
Drugs
rituximabmycophenolate mofetil
03
Conditions
pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD)
Beyond the preview
Go deeper on 2023-510507-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510507-21-00.